Pediatrix Medical Group, Inc. shares rise 1.47% intraday after GeneDx published SeqFirst study data.

Pediatrix Medical Group, Inc. rose 1.47% in intraday trading. The company's stock price increase may be attributed to the recent publication of the SeqFirst study by GeneDx, a leader in genomic insights, which supports the application of rapid exome sequencing (rES) and rapid genome sequencing (rGS) as a first-tier test for non-critical pediatric inpatients. The study, conducted in partnership with Seattle Children's clinical genetics team, demonstrated improved diagnostic rates, which could positively impact Pediatrix Medical Group, Inc. as it operates in the healthcare sector.